Peptide Atlas · Peptide

Buserelin

Buserelin is a luteinising-hormone-releasing-hormone (GnRH) agonist; in nine men with advanced prostate cancer, LH first rose and then fell, and testosterone dropped to castrate levels within three weeks and stayed there for 24 weeks.

established

provisional
PubChem 50225
2 citations
0 discussions
0 followers
Buserelin acetate
D-Ser(tBu)6-des-Gly10-GnRH ethylamide
Suprefact

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

established — replicated in humans, or settled by a regulator

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

- emerging
  Claim: Buserelin produced sustained castrate testosterone levels in advanced prostate cancer standing
- resolved
Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach?
Borgmann V, Hardt W, Schmidt-Gollwitzer M, Adenauer H, Nagel R
pmid 6122893
- established
  Claim: Dienogest matched intranasal buserelin for endometriosis pain with less bone loss (phase III RCT) standing
- resolved
Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis--a randomized, double-blind, multicenter, controlled trial.
Harada T, Momoeda M, Taketani Y, Aso T, Fukunaga M, Hagino H, Terakawa N
pmid 18653184

A claim's standing is its latest row in an append-only history; a tombstone names the later evidence and the reason. The Graveyard and the Resurrection Yard.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.